Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2368706 | 0.81 | RAB9A (0.97) | RAB9ANPC1SMN1; SMN2GAACHEK1 | |
| SCHEMBL20514191 | 0.81 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2GAACHEK1 | |
| SCHEMBL2369146 | 0.78 | GAA (1.00) | RAB9ANPC1SMN1; SMN2GAACHEK1 | |
| SCHEMBL2369000 | 0.78 | GAA (0.60) | RAB9ANPC1SMN1; SMN2GAACHEK1 | |
| SCHEMBL2369558 | 0.78 | GAA (0.73) | RAB9ANPC1SMN1; SMN2GAACHEK1 | |
| SCHEMBL2368821 | 0.75 | CHEK1 (1.00) | RAB9ANPC1SMN1; SMN2GAACHEK1 | |
| SCHEMBL2369157 | 0.75 | GAA (0.69) | RAB9ANPC1SMN1; SMN2GAACHEK1 | |
| SCHEMBL2368692 | 0.72 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2GAACHEK1 | |
| SCHEMBL2368426 | 0.72 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2GAACHEK1 | |
| SCHEMBL2368460 | 0.72 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2GAACHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022076-B2 | Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents | XENTION LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| EP-1641803-B3 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2010-12-08 | — | — | EP | disclosed |
| EP-1641803-B1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2009-03-18 | — | — | EP | disclosed |
| CN-1823071-A | Thienopyrimidine derivatives as potassium channel inhibitors | XENTION DISCOVERY LTD (GB) | 2006-08-23 | — | — | CN | disclosed |
| EP-1641803-A1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Xention Discovery Limited (GB) | 2006-04-05 | — | — | EP | disclosed |
| US-20050026935-A1 | Compounds | XENTION DISCOVERY LTD. | 2005-02-03 | — | — | US | disclosed |
| WO-2004111057-A1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION DISCOVERY LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026935-A1 | Compounds | KCNJ11, KCNJ1, KCNH1 | RAB9A 1622/4885NPC1 125/4885SMN1; SMN2 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.